Specify a stock or a cryptocurrency in the search bar to get a summary
Ikena Oncology Inc
IKNAIkena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Address: 645 Summer Street, Boston, MA, United States, 02210
Analytics
WallStreet Target Price
8.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IKNA
Dividend Analytics IKNA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IKNA
Stock Valuation IKNA
Financials IKNA
Results | 2019 | Dynamics |